Brain Tumor Drugs Market Forecasts to 2028 - Global Analysis By Therapy (Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies), Indication (Pituitary Tumors, Meningioma, Glioblastoma and Glioma), Drugs (Bevacizumab, Temozolomide and Other Drugs) and Geography
According to Stratistics MRC, the Global Brain Tumor Drugs Market is accounted for $2.56 billion in 2022 and is expected to reach $4.80 billion by 2028 growing at a CAGR of 11.0% during the forecast period. An abnormal mass of tissue called a brain tumour is made up of rapidly and uncontrollably growing brain cells. Brain tumours can be divided into two categories: primary brain tumours and metastatic brain tumours. Primary brain tumours are those that develop in the brain's tissues and its surrounding area. The majority of brain tumour cases are caused by this form of tumour.
According to the American Cancer Society, in the U.S., the number of cases of brain cancer was approximately 24,530 in 2021. Additionally, the increasing research & development of these drugs and the growing government funding for them are expected to support the market growth.
Rising Prevalence of Brain Cancer Cases
Globally, the incidence of cancer is rising as a result of factors like changing food habits, altering lifestyles, growing urbanization, and rising smoking rates. For instance, the WHO estimates that approximately 23.0% of adults worldwide consume tobacco. As a result, the global increase in cancer cases is being aided by the adult population's increasing smoking prevalence. Due to the increased prevalence of various cancer forms, the rate of diagnosis and treatment is also rising.
Comparatively Lower Diagnosis and Treatment Rates
In developing nations compared to developed nations, brain cancer is diagnosed and treated at substantially lower rates. For instance, 14.82 brain tumours per 100,000 people were detected in China in 2021. Moreover, compared to developed nations, the treatment rate for brain tumours is incredibly low. Although diagnosis and treatment of brain tumours are on the rise in developing countries, the market adoption of these drugs is being constrained by their high cost. Additionally, the production of these drugs in developing nations is constrained by the lack of reimbursement regulations in such nations for the treatment of brain tumours.
Strong Presence of Pipeline Candidates
Manufacturers all over the world are being required to participate in substantial research and development operations due to the urgent need to provide advanced patient care for a variety of brain disorders. They are conducting innovative research to introduce combination medicines using current or brand-new drug molecules. As a result, there are a large number of drug candidates in the pipeline for curing brain tumours.
Use of targeted therapies
Increased use of targeted therapies is exerting pressure on the market for pharmaceuticals to treat brain tumors. The use of drugs or other substances that precisely target molecules involved in the emergence of cancer cells as opposed to molecules involved in normal cell activity is recognised as targeted cancer therapy. Targeted cancer therapies aim to eliminate malignant cells while sparing healthy cells from damage.
The COVID-19 epidemic had a negative effect on the market. Throughout the time, the market expanded steadily. Reduced rates of brain tumour diagnosis and treatment were among the factors contributing to the market's decline during that period. The market only experienced moderate growth during the COVID-19 pandemic due to production and supply chain delays that leading market competitors had to cope with.
The glioma segment is expected to be the largest during the forecast period
Due to the increasing prevalence of malignant brain tumours worldwide and the rising number of drug launches for the treatment of glioblastoma, which will promote market expansion, the glioma segment, which dominated the market in 2021, is anticipated to rise and is projected to be the largest during the forecast period. For instance, the U.S. FDA granted IND approval to CNS Pharmaceuticals, Inc. in December 2020 for its drug Berubicin, which is used to treat metastatic cancer of the brain and central nervous system.
The targeted therapy segment is expected to have the highest CAGR during the forecast period
Owing to rising acceptance and shifting preferences among consumers toward targeted therapy for cancer treatment, the targeted therapy segment is anticipated to experience considerable growth during the forecast period. Additionally, it is anticipated that rising clinical collaborations for the development of these drugs and an increase in targeted therapy drug product launches will boost market expansion.
Region with largest share:
North America dominated the largest market share during the projection period due to a rise in regional sales of drugs for brain tumors. This is indicated by the rising glioblastoma diagnosis rates in the United States. The population's ability to spend money and access to cutting-edge therapies both play a role in this dominance. Furthermore, the market's growth is driven by the region's rapid product launches, regulatory approvals, and the presence of key players.
Region with highest CAGR:
Due to increasing government awareness campaigns and investments in the research and development of novel brain tumour drugs, Europe had the highest CAGR and is expected to continue during the projection period. Furthermore, the market in Europe is primarily driven by the prevalence of primary brain tumours, favourable regulatory environments in major European nations, and a growing concentration of scientific research for the development of brain tumour drugs.
Key players in the market
Some of the key players in Brain Tumor Drugs market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Pfizer Inc, Novartis AG, Amneal Pharmaceuticals LLC., NextSource Pharmaceuticals, LLC, Amgen Inc, Bristol-Myers Squibb, Emcure Pharmaceuticals and AstraZeneca
In September 2022, F. Hoffmann-La Roche Ltd. announced its agreement to acquire Good Therapeutics. Upon this acquisition, the company will gain rights to Good Therapeutics’ platform technology applicable to a wide range of areas, including cancer, autoimmune diseases, metabolic disease, and pain management
In June 2022, Novartis AG received FDA approval for Tafinlar + Mekinist for the treatment of pediatric and adult patients suffering with solid tumors with BRAF V600E mutation. The BRAF mutations drive tumor growth in more than 20 tumor types, including brain, thyroid, and others.
• Targeted Therapy
• Other Therapies
• Pituitary Tumors
• Other Drugs
• North America
Rest of Europe
• Asia Pacific
Rest of Asia Pacific
• South America
Rest of South America
• Middle East & Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook